These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38024590)

  • 1. The role of tocilizumab in the treatment of post-transfusion hyperhaemolysis.
    Desai N; Peters J; Davies E; Sharif J
    EJHaem; 2023 Nov; 4(4):1096-1099. PubMed ID: 38024590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperhaemolytic Syndrome in Sickle Cell Disease: Clearing the Cobwebs.
    Madu AJ; Ugwu AO; Efobi C
    Med Princ Pract; 2021; 30(3):236-243. PubMed ID: 33176303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-transfusion hyperhaemolysis in a patient with sickle cell disease: use of steroids and intravenous immunoglobulin to prevent further red cell destruction.
    Cullis JO; Win N; Dudley JM; Kaye T
    Vox Sang; 1995; 69(4):355-7. PubMed ID: 8751307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of post-transfusion hyperhaemolysis syndrome in Sickle Cell Disease with the anti-IL6R humanised monoclonal antibody Tocilizumab.
    Sivapalaratnam S; Linpower L; Sirigireddy B; Agapidou A; Jain S; Win N; Tsitsikas DA
    Br J Haematol; 2019 Sep; 186(6):e212-e214. PubMed ID: 31368112
    [No Abstract]   [Full Text] [Related]  

  • 5. Hyperhaemolysis caused by anti-HI antibodies in a patient with myelodysplastic syndrome following a first ever red cell transfusion.
    Hinton R; Haji R; Kaczmarski R; Layton M; Danga A
    Transfus Med; 2023 Aug; 33(4):349-351. PubMed ID: 37186414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatal Delayed Haemolytic Transfusion Reaction and Hyperhaemolysis Syndrome in a Pregnant Woman with Sickle Cell Anaemia.
    Asnawi AW; Sathar J; Mohamed R; Deraman R; Kumaran S; Hamid SS; Zakaria MZ
    Indian J Hematol Blood Transfus; 2016 Jun; 32(Suppl 1):251-3. PubMed ID: 27408406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: A systematic review.
    Jacobs JW; Stephens LD; Allen ES; Binns TC; Booth GS; Hendrickson JE; Karafin MS; Tormey CA; Woo JS; Adkins BD
    Br J Haematol; 2023 Jun; 201(6):1025-1032. PubMed ID: 37074146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful management of the potentially fatal hyperhaemolysis syndrome of sickle cell anaemia with a regimen including bortezomib and Hemopure.
    Epstein SS; Hadley TJ
    J Clin Pharm Ther; 2019 Oct; 44(5):815-818. PubMed ID: 31237703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttransfusion hyperhemolysis is arrested by targeting macrophage activation with novel use of Tocilizumab.
    Lee LE; Beeler BW; Graham BC; Cap AP; Win N; Chen F
    Transfusion; 2020 Jan; 60(1):30-35. PubMed ID: 31642065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of hyperhaemolysis syndrome in a pregnant Chinese woman with β-thalassemia during perinatal transfusion.
    Wu Y; Ji Y; Dai B; Guo F; Wu Y; He Z; Mo C; Wu S; Hu Y
    Transfus Med; 2021 Feb; 31(1):24-29. PubMed ID: 33331032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathological evidence for macrophage activation driving post-transfusion hyperhaemolysis syndrome.
    Win N; Lucas S; Hebballi S; McKernan A; Hamilton R; Robinson I; Chen F
    Br J Haematol; 2019 Aug; 186(3):499-502. PubMed ID: 31020643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperhemolysis in a patient with sickle cell disease and recent SARS-CoV-2 infection, with complex auto- and alloantibody work-up, successfully treated with tocilizumab.
    Fuja C; Kothary V; Carll TC; Singh S; Mansfield P; Wool GD
    Transfusion; 2022 Jul; 62(7):1446-1451. PubMed ID: 35588309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of intravenous immunoglobulin and intravenous methylprednisolone in hyperhaemolysis syndrome in sickle cell disease.
    Win N; Yeghen T; Needs M; Chen FE; Okpala I
    Hematology; 2004; 9(5-6):433-6. PubMed ID: 15763986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful Management of Severe Hyperhaemolysis with Combined Tocilizumab and Rituximab in Non-Transfusion-Dependent Thalassaemia: A Case Report.
    El Afifi AM; Saeed AM; Fekry GH; Mostafa MA; Elmetwally RA; Hamed IM; Hussein AN; Hasanien GM
    Transfus Med Hemother; 2023 Feb; 50(1):66-70. PubMed ID: 36818772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab in the management of posttransfusion hyperhemolysis syndrome in sickle cell disease: The experience so far.
    Meenan J; Hall R; Badle S; Chatterjee B; Win N; Tsitsikas DA
    Transfusion; 2022 Mar; 62(3):546-550. PubMed ID: 35092617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperhaemolysis syndrome in a patient with myelofibrosis.
    Treleaven JG; Win N
    Hematology; 2004 Apr; 9(2):147-9. PubMed ID: 15203871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When a transfusion in an emergency service is not really urgent: hyperhaemolysis syndrome in a child with sickle cell disease.
    Chinchilla Langeber S; Osuna Marco MP; Benedit M; Cervera Bravo Á
    BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29588281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed haemolytic transfusion reaction and hyperhaemolysis complicating peri-operative blood transfusion in sickle cell disease.
    McGlennan AP; Grundy EM
    Anaesthesia; 2005 Jun; 60(6):609-12. PubMed ID: 15918834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute Hyperhemolysis Syndrome in a Patient with Known Sickle Cell Anemia Refractory to Steroids and IVIG Treated with Tocilizumab and Erythropoietin: A Case Report and Review of Literature.
    Menakuru SR; Priscu A; Dhillon V; Salih A
    Hematol Rep; 2022 Jul; 14(3):235-239. PubMed ID: 35893156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperhaemolytic transfusion reaction in two β-thalassaemia major patients: The role of eculizumab.
    Pantelidou D; Pilalas D; Daios S; Polychronopoulos G; Papadopoulou D; Perifanis V; Savopoulos C; Kaiafa G
    J Clin Pharm Ther; 2022 Mar; 47(3):411-414. PubMed ID: 34397109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.